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Abstract: Background and aims: Identification of patients with increased risk of mortality represents
an important prerequisite for an adapted adequate and individualized treatment of critically ill
patients. Circulating micro-RNA (miRNA) levels have been suggested as potential biomarkers at the
intensive care unit (ICU), but none of the investigated miRNAs displayed a sufficient sensitivity or
specificity to be routinely employed as a single marker in clinical practice. Methods and results: We
recently described alterations in serum levels of 7 miRNAs (miR-122, miR-133a, miR-143, miR-150,
miR-155, miR-192, and miR-223) in critically ill patients at a medical ICU. In this study, we re-analyzed
these previously published data and performed a combined analysis of these markers to unravel
their potential as a prognostic scoring system in the context of critical illness. Based on the Youden’s
index method, cut-off values were systematically defined for dysregulated miRNAs, and a “miRNA
survival score” was calculated. Patients with high scores displayed a dramatically impaired prognosis
compared to patients with low values. Additionally, the predictive power of our score could be
further increased when the patient’s age was additionally incorporated into this score. Conclusions:
We describe the first miRNA-based biomarker score for prediction of medical patients’ outcome
during and after ICU treatment. Adding the patients’ age into this score was associated with a further
increase in its predictive power. Further studies are needed to validate the clinical utility of this score
in risk-stratifying critically ill patients.
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1. Introduction
In the last years, many circulating biomarkers have been evaluated for their potential to categorize
critically ill patients according to their estimated prognosis during or after intensive care unit (ICU)
treatment. In the context of “personalized medicine” approaches, such information were suggested to
define individualized ICU management strategies based on early risk stratification, as was recently
proposed in the Surviving Sepsis Campaign [1]. However, it became apparent that both the specificity
and sensitivity of most (if not all) single markers in the context of critical illness are too low to justify
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their use in clinical routine [2]. In the absence of a single accepted biomarker, many authors have
proposed not only attempting to identify new classes of biomarkers, but also to combine several
clinical or laboratory biomarkers to improve their potential regarding the prediction of ICU patients’
prognosis [3–5].
miRNAs are small non-coding RNA molecules (~22 nucleotides) that repress the translation of
their target mRNAs by binding to their 3′-untranslated region (UTR), and thereby play an important
role in various physiological and pathological processes [6]. Besides their role in the regulation
of gene expression, circulating miRNAs have emerged as a new class of biomarkers for various
diseases such as organ fibrosis [7,8], systemic inflammation, and sepsis [9]. However, despite an
initial enthusiasm in the field, miRNA-based biomarkers have not yet entered clinical routine due
to incoherent normalization and non-standardized sample handling protocols. Moreover, it was
recognized that similar to protein-based biomarkers, concentrations of circulating miRNAs also only
display a limited diagnostic and prognostic power when used as stand-alone biomarkers in the setting
of critical illness [10].
In the present study, we demonstrate that a composite score containing selected miRNAs has a
considerably higher performance in identifying patients with a favorable prognosis during or after
ICU treatment compared to individual miRNAs. Interestingly, the integration of the patient’s age into
this miRNA-based score leads to a further increase in its sensitivity and specificity.
2. Patients and Methods
2.1. Study Design
The cohorts of patients for analysis of single miRNAs are described elsewhere in detail [9,11–15].
The cohort of patients included in the present analysis is described within Tables 1 and 2. All patients
included in the study provided written informed consent, and the ethics committee approved this
consent procedure. The study protocol is in line with Declaration of Helsinki and was approved by
the local ethics committee (ethics committee of the University Hospital Aachen, RWTH-University,
Aachen, Germany, reference number EK 150/06). All patients were treated in accordance with current
guidelines for treatment of sepsis (Surviving Sepsis Campaign) and specific guidelines of the respective
boards. The clinical course of patients was followed up for a period of three years by directly contacting
the patients, the patients’ relatives, or their primary care physician.
Table 1. Baseline characteristics of the study population.
Parameter All Patients
Number 204
Sex (male/female) 132/72
Age median (range) [years] 63 (18–89)
APACHE-II score median (range) 16 (2–40)
SAPS2 score median (range) 43 (8–79)
ICU days median (range) 7 (1–83)
Death during ICU [%] 22.1
Ventilation [%] 64.7
Body mass index median (range) [kg/m2] 26.1 (16.6–86.5)
Creatinine (range) [mg/dL] 1.3 (0–15)
WBC median (range) [×103/µL] 12.2 (0.1–67.4)
CRP median (range) [mg/dL] 100 (<5–230)
Procalcitonin median (range) [µg/L] 0.71 (0–180.6)
Interleukin-6 median (range) [pg/mL] 105 (0–83,000)
INR median (range) 1.18 (0–9.2)
APACHE, Acute Physiology and Chronic Health Evaluation; CRP, C-reactive protein; ICU, intensive care unit; INR,
international normalized ratio; SAPS, simplified acute physiology score; WBC, white blood cell count.
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Table 2. Disease etiology of the study population.
Sepsis Non-Sepsis
n = 127 n = 77
Sepsis critical illness
Source of infection n (%)
Pulmonary 67 (52.8)
Abdominal 28 (22.0)
Urogenital 3 (2.4)
Other 29 (22.8)
Non-sepsis critical illness
n (%)
Cardiopulmonary disease 26 (33.8)
Decompensated liver cirrhosis 11 (14.3)
Non-sepsis other 40 (51.9)
2.2. Extraction of miRNA and qPCR
MiRNA extraction and qPCR was described elsewhere in detail [9,11–15]. In brief, blood was
collected using serum monovettes (Sarstedt, Nümbrecht, Germany), centrifuged for 8 min at 2000× g
using a Rotixa 50 centrifuge (Hettich, Tuttlingen, Germany). Then, 400 µL serum was spiked with
miScript miRNA mimic SV40 (Qiagen 2 µM, 1 µL/100 µL serum) for sample normalization. Afterwards,
800 µL phenol (Qiagen, Hilden, Germany) and 200 µL chloroform were added to the sample and
mixed vigorously for 15 s, followed by an incubation at room temperature for 10 min. Samples
were centrifuged for 15 min at 12,000× g until complete phase separation. The aqueous phase was
precipitated with 500 µL 100% isopropanol and 2 µL glycogen (Fermentas, St. Leonroth, Germany)
overnight at −20 ◦C. After centrifugation at 4 ◦C for 30 min (12,000× g), the pellets were washed once
with 70% ethanol. Precipitated RNA was resuspended in 30 µL RNase-free water (Ambion, Austin, TX,
USA). For quantitative real-time polymerase chain reaction (PCR), 5 µL of extracted total RNA was used
to synthesize complementary deoxyribonucleic acid (cDNA) utilizing a miScript Reverse Transcriptase
Kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. cDNA samples (2 µL) were
used for quantitative real-time PCR in a total volume of 25 µL using the miScript SYBR Green PCR Kit
(Qiagen) and miRNA specific primers (Qiagen, primer sequences available online) on a qPCR machine
(Applied Biosystems 7300 Sequence Detection System, Applied Biosystems, Foster City, CA, USA).
Data were generated and analyzed using the SDS 2.3 and RQ manager 1.2 software packages.
2.3. Statistical Analysis
All statistical analyses were performed with SPSS (SPSS, Chicago, IL, USA) as described
previously [16]. Data are displayed as median and range considering the skewed distribution
of most parameters. Gaussian distribution was tested with Kolmogorov–Smirnov test. Differences
between two groups were assessed by Student’s t-test or Wilcoxon rank-sum test, and multiple
comparisons between more than two groups were conducted by ANOVA with Bonferroni test or
Dunns test for post-hoc analysis. Box and whisker plot graphics illustrate a statistical summary. Here,
the box represents the median with interquartile range (IQR), and the “whiskers” include all values
smaller than the upper quartile plus 1.5*IQR and larger than the lower quartile minus 1.5*IQR. Values
outside of the whiskers are displayed as separate points and represent outliers. All values, including
outliers, were included for statistical analyses. Correlations between variables were analyzed using the
Spearman correlation test. Receiver operating characteristic (ROC) curve analysis and the derived area
under the curve (AUC) statistic provide a global and standardized appreciation of the accuracy of a
marker or a composite score for predicting an event. ROC curves were generated by plotting sensitivity
against 1-specificity. Optimal cut-off values were calculated by maximizing the Youden’s index, which
is defined as sensitivity + specificity − 1 [17]. Kaplan–Meier curves were plotted to display the impact
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on survival and between-group differences were assessed using the log-rank test. Cox regressions
were used to identify factors predicting ICU mortality or overall mortality. All reported p-values are
two-tailed, and a p-value of less than 0.05 is considered statistically significant.
3. Results
3.1. Alterations of Circulating miRNA Concentrations in Critically Ill Patients
We recently described alterations in serum levels of miR-122, miR-133a, miR-143, miR-150, miR-155,
miR-192, and miR-223 in patients that were treated on our medical intensive care unit [9,11–15]. In this
study, we re-analyzed these previously published data and performed a combined analysis of these
markers in critically ill patients. Only patients with valid results for all seven miRNAs were included
in the present analysis, which was the case for 204 patients (Tables 1 and 2). We found significantly
higher levels of miR-122, miR-133a, miR-155, and miR-192 in critically ill patients when compared to
healthy controls, while levels of miR-150 and miR-223 were slightly lower in the patient group, which
is in line with our previous reports (Table 3). Of the 204 patients included in the present analysis, 127
fulfilled the Sepsis-3 criteria [18] at the time point of admission to the ICU (Table 2). In line with our
previous results, only miR-133a levels were altered in patients with sepsis compared to patients with
non-septic disease (Table 3). Out of the 204 patients, 45 died during ICU treatment and an additional
40 patients died during the long-term observation period (post-ICU/post-hospital). Similar to our
previous reports, concentrations of miR-133a were significantly elevated, whereas levels of miR-143
as well as miR-223 were significantly decreased in patients who did not survive the ICU stay, and
miR-133a (up) and miR-150 (down) displayed a significant deregulation in patients that displayed an
unfavorable overall prognosis (Table 3).
3.2. A Three miRNA Score Predicts Patients’ Survival in ICU Treatment
To analyze the potential of combining different miRNAs for the prediction of patients‘ prognosis,
we next included those miRNAs that displayed a significant down-regulation in patients who did
not survive ICU treatment (Table 3) into ROC curve analysis and calculated an “optimal” statistical
cut-off value for each miRNA regarding the discrimination between survivors and non-survivors by
using the Youden’s index method (Figure 1A). We next validated the respective cut-off values for each
individual miRNA in Kaplan–Meier survival analysis, revealing clear differences in patients’ ICU
survival when they were categorized using the calculated cut-offs (Figure 1B–D). Considering these
results, we subsequently hypothesized that a combined score consisting of the significantly regulated
miRNAs (miR-133a, miR-143, and miR-223) might outperform individual miRNA measurements
regarding the discrimination between patients with a favorable prognosis during ICU treatment and
those with a higher risk for ICU mortality. For this, we used the cut-off values derived from the area
under the curve (AUC) analysis. Patients with a higher (in case of up-regulated miRNAs) or lower
(in case of down-regulated miRNAs) concentration than the respective cut-off values were given one
point for each individual dysregulated miRNA. Patients not fulfilling these criteria did not receive a
point. All points were added to an “miRNA ICU survival score” (Figure 2A). By applying this score
within our cohort, three different subgroups became apparent: Patients with 3 points in our survival
score (“all miRNAs positive”) displayed an ICU mortality of 67%, while, in sharp contrast, patients
with 0 points (“all miRNAs negative”) displayed a mortality rate of only 5%. Patients with 1 or 2
points had an intermediate risk of dying during their ICU stay (21%). In addition, we performed
Kaplan–Meier curve analysis with our ICU score as the stratifying variable. This analysis confirmed
that higher values were associated with an unfavorable prognosis (Figure 2B).
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Table 3. Comparison of the data from the current analysis with the respective published data.
Mir-122 Mir-133a Mir-143 Mir-150 Mir-155 Mir-192 Mir-223
Published
[11]
204
Patients
Cohort
Published
[9]
204
Patients
Cohort
Published
* [19]
204
Patients
Cohort
Published
[12]
204
Patients
Cohort
Published
[13]
204
Patients
Cohort
Published
[14]
204
Patients
Cohort
Published
[15]
204
Patients
Cohort
Patients vs.
Control ↑ ↑ ↑ ↑ = = = = ↑ ↑ ↑ rauf ≈(↓) ↓
Sepsis vs.
Non-Sepsis = = ↑ ↑ = = = = = = = = = =
ICU Survival vs.
Non-Survival = = ↓ ↓ ↑ ↑ = = = = = = ↑ ↑
Overall Survival
vs. Non-Survival = = ↓ ↓ = = ↑ ↑ = = = = = =
* Disease markers, in pres.
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Figure 1. (A) ROC analysis comparing all seven single miRNAs at admission for ICU mortality.
(B–D) Optimal cutoffs were calculated for miR-133a, miR-143, and miR-223 using Youden’s index to
discriminate between ICU non-survivors and survivors. Kaplan–Meier curves with miR-133a, miR-143,
and miR-223 as single biomarker are displayed.
Figure 2. (A) The individual “miRNA survival score” was calculated as described in the text. In brief,
patients with a higher (in the case of miR-133a) or lower (in the case of miR-143 and miR-223) levels
than the respective cut-off were given one point for each individual dysregulated miRNA. All points
were added to an “ICU survival score”, (B) Kaplan–Meier curve analysis of ICU patients demonstrates
that patients with a high “ICU survival score” had an increased short-term mortality compared to
other patients; p-values are given in the figure. (C) Age was included in the “ICU survival score”.
Patients older than 72.5 years received one additional point. (D) Kaplan–Meier curve analysis of ICU
patients demonstrates that patients with higher “ICU survival score + age” had an increased short-term
mortality compared to other patients; p-values are given in the figure.
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It was previously described that elderly patients have a disproportionately higher morbidity and
mortality from sepsis [20]. We therefore hypothesized that adding the patient’s age to our score might
further increase its accuracy to predict the individual ICU prognosis. We first calculated a cut-off
value that best indicated the patient’s prognosis, as previously described (72.5 years). By including the
patient’s age as an additional item (if age >72.5 years then 1 point, else 0 points), the performance of
our score to estimate the patient’s outcome could be further increased: Patients with 4 points (“all
miRNAs positive” and age >72.5 years) displayed an ICU mortality of 90%; patients with 0 points (“all
miRNAs negative” and age <72.5 years) displayed a mortality of 0%, clearly highlighting that the use
of our score allows to discriminate between low and high risk patients (Figure 2C,D).
Besides age, the presence of septic disease might also have a critical impact on the patient’s
survival. To exclude that our ICU survival score was biased by sepsis, we analyzed the proportions of
patients with lower or higher score values in the subgroup of patients with septic diseases and the
subgroup of patients with a different etiology of critical illness. Importantly, we found no difference in
the distribution of patients with higher or lower risk according to our score between these subgroups,
highlighting that our score represents a reliable predictor of prognosis in medical ICU patients with or
without sepsis (Supplementary Figure S1).
3.3. A Two miRNA Score Predicts Patients’ Long-Term Prognosis
Similar to the ICU survival score, we included those miRNA that displayed a significant
down-regulation in patients who did not survive the long-term observation period compared to
survivors into ROC curve analysis (Figure 3A) and calculated an “optimal” statistical cut-off value for
each miRNA for distinguishing between survivors and non-survivors by using the Youden’s index
method. We next validated these cut-off values for each individual miRNA in Kaplan–Meier survival
analyses (Figure 3B,C) and generated an “miRNA overall survival score” by analyzing patients’ survival
with respect to their individual score. If the miR-133a level was higher than 4.3 [AU], the patients were
assigned 1 point, else 0 points, and similarly, if the miR-150 level was lower than 22.7 [AU], patients
were assigned 1 point, else 0 points. Patients with 2 points in our “overall survival score” (“both
miRNAs positive”) displayed a considerably higher overall mortality (83%) compared to patients with
0 points (“both miRNAs negative”, overall mortality: 18%), which was additionally confirmed by
Kaplan–Meier curve analysis with our overall survival score as the stratifying variable (Figure 4A,B).
This analysis confirmed that higher score values were associated with an unfavorable prognosis.
Again, by including the patient’s age as an additional item (if age >68.5 years then 1 point, else 0
points), the performance of our score to estimate patients’ overall survival could be further increased:
Patients with 3 points (“all miRNAs positive” and age >68.5 years) displayed an overall mortality of
86%; patients with 0 points (“both miRNAs negative” and age <68.5 years) displayed a mortality rate
of only 11%. In line, Kaplan–Meier curve analysis revealed a significantly impaired long-term outcome
for patients who had a higher overall survival score (Figure 4C,D).
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Figure 3. (A) ROC analysis comparing all miRNAs at admission for overall mortality. (B,C) optimal
cut-offs were calculated for miR-133a and miR-150 using Youden’s index to discriminate between
overall non-survivor and survivor. Kaplan–Meier curves of ICU patients with miR-133 and miR-150 as
single biomarker.
Figure 4. (A) The individual “overall survival score” was calculated as described in the text. In brief,
patients with higher (in case of miR-133a) or lower (in case of miR-150) levels than the respective
cut-off were given one point for each individual dysregulated miRNA. All points were added to an
“overall survival score”, (B) Kaplan–Meier curve analysis of ICU patients demonstrates that patients
with higher “overall survival scores” had an increased overall mortality compared to other patients;
p-values are given in the figure. (C) Age was included into the score. Patients older than 68.5 years
received one additional point. (D) Kaplan–Meier curve analysis of ICU patients demonstrates that
patients with higher scores had an increased overall mortality compared to other patients; p-values are
given in the figure.
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4. Discussion
In the present study, we demonstrate that a panel of miRNAs is predictive for the patients´
outcome during and after ICU treatment. Our multimarker approach improves the prognostic power in
comparison to stand-alone marker approaches previously published in the field of miRNA research in
critical care medicine. Together, such prognostic scoring systems could be highly relevant for guiding
the individual treatment of critically ill patients at admission to the ICU.
Despite continuous advances in diagnostic modalities, the initial triage, as well as the diagnostic
and therapeutic management of critically ill patients, have remained a major clinical challenge. In this
context, besides specific triage systems, various laboratory markers potentially allowing decisions
on the patients’ treatment and their individual clinical course were proposed. As such, apart from
routinely used laboratory markers (e.g., C-reactive protein or procalcitonin; [2]), a variety of different
experimental protein-based markers such as Ghrelin, Leptin, Resistin, and Osteopontin [16,21–23]
were tested. However, the lack of prognostic sensitivity and specificity for individual markers, as
well as marker-specific confounding parameters (like sepsis or organ failure), hamper the translation
into clinical routine algorithms [2,24]. Compared to ’conventional’ protein-based markers, circulating
miRNAs harbor several advantages: Circulating miRNAs are extraordinarily stable towards conditions
that would usually degrade most proteins in serum or blood [25]. In addition, miRNAs do not have
known postprocessing modifications, and with their size, as well as their chemical composition, they
are much less complex than most other biological biomarkers [26]. Therefore, many authors have
hypothesized that circulating miRNAs might perform better in the detection of sepsis or prognosis
prediction in critically ill patients. As an example, miR-150 levels were found to be down-regulated in
patients with urosepsis [27], as well as in a cohort of critically ill patients comprising various disease
etiologies and severities [12]. Besides miR-150, miR-122, miR-133a, miR-146a, and miR-223 were
identified to be indicative of the patients´ fate during and after ICU treatment [10]. However, their
low sensitivity and specificity has deferred the use in clinical routine until now. In this context, we
now provide the first multimarker, miRNA-based score for prognosis prediction in critical illness
and sepsis. Importantly, our miRNA panel is biologically plausible as it incorporates biomarkers
involved in inflammation and infection, key components of the pathophysiology of critical illness:
We recently described alterations of miR-133a, miR-150, miR-155, and miR-193b* concentrations after
cecal pole ligation and puncture-induced sepsis in mice [9]. Moreover, a dysregulation of miR-143
and miR-223 was found in leukocytes after LPS administration, as well as in various inflammatory
diseases [28]. miR-122 and miR-192 represent liver-specific miRNAs with a specific dysregulation in
hepatic injury and failure, representing a key feature of organ malperfusion associated with critical
illness and sepsis [11]. In the present manuscript, we demonstrate that, besides miR-143, levels
of all these miRNAs are altered in critical illness, supporting the selection of this 7-miRNA panel.
Interestingly, within these miRNAs, only miR-133a, miR-143, and miR-223 were found to be regulated
with respect to patients’ ICU survival, while only miR-133a and miR-150 were regulated with respect
to patients’ overall survival, highlighting that individual miRNAs might specifically indicate distinct
features of critical illness. It therefore seems likely that the integration of these miRNAs into a score
might provide a more comprehensive picture, and therefore also provide a more accurate estimation of
patients’ prognosis compared to the analysis of a single miRNA in this setting.
Despite important advances in the field of miRNA research, it is important to note that the
inter-study variances in terms of miRNA regulation patterns are enormous, and different studies have
shown even opposing results with respect to the deregulation of miRNA levels in critical illness and
sepsis [15,29,30]. Though miRNAs are very stable molecules in serum or plasma, it is likely that a
lack of standardization regarding sample collection, data normalization, and analysis might have
biased certain studies. In an attempt to avoid theses biases, in the present study sample, collection and
handling followed strict protocols, e.g., by using spiked-in RNA (SV-40) for normalization, which is
regarded as the ‘gold standard’ by most authors [31–33]. Finally, the cut-off values for our score were
defined using the broadly accepted Youden’s index method, leading to certain differences with respect
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to cut-off values from previous studies [9,11,12,15]. These measures were taken to overcome technical
challenges of miRNA analysis from serum or plasma, giving rise to the expectation that circulating
miRNAs might become novel, highly attractive biomarkers. Their value as prognostic biomarkers
might be further increased through combination with other clinical markers, which is supported by
the fact that integrating the patient’s age into our score further increased the predictive accuracy.
Such scoring systems might help to stratify patients into those with a need for intensifying treatment
measures and those with a more favorable prognosis that might, e.g., be treated in non-intensive care
settings and are not in need of intensive treatment modalities usually applied in medical ICUs.
In summary, our study is the first to demonstrate the prognostic value of an miRNA-based scoring
system in ICU patients. High scores upon admission were closely associated with increased ICU and
long-term mortality, and lower scores reliably indicated a favorable prognosis. Our data therefore
provide evidence for a potential role of serum miRNA concentrations, and especially for combining
different serum miRNA levels as an innovative prognostic tool in critically ill patients. Such data
might help to improve prognostic assessments in critically ill patients upon admission to the ICU and
should provoke further research to validate our results in larger and prospective studies on critically
ill patients.
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